Amissa has launched an AI platform designed to help clinicians track menopause and perimenopause symptoms over time. The company is a recipient of the National Institutes of Health’s Small Business Innovation Research grant.
The platform aggregates data from three sources: the Menopause Rating Scale questionnaire administered during patient intake, patient self-reported symptom tracking, and wearable integrations with Apple Watch, Oura, Garmin, and Whoop. This information is consolidated into a clinical record within the provider’s EHR.
Amissa is currently working with 10 clinical practices across the United States, including Helia Health. Providers pay a per-clinician fee for the platform.
“Menopause symptoms don’t move in a straight line,” said Dr. Ariel Haddad, OB-GYN and founder of Helia Health. “When I can see what’s improving, what’s worsening, and what’s staying the same between visits, I can adjust care with confidence and show patients that their experience is being taken seriously.”
The company positions itself as a B2B clinical tool rather than a direct-to-consumer product.
